Oncology Learning Network
@OncLearnNetwork
Followers
1,041
Following
427
Media
1,449
Statuses
2,144
Oncology Learning Network® is an online resource for the latest updates in oncology practice. Official digital home for @GreatDebatesCME and @LLMCongress .
Joined April 2018
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
TLP HAIRPIN OF LOVE
• 480922 Tweets
#ปิ่นภักดิ์EP5
• 467143 Tweets
Charles
• 257030 Tweets
#ItalianGP
• 256726 Tweets
نيوكاسل
• 197266 Tweets
Monza
• 161180 Tweets
Ferrari
• 153611 Tweets
India Will Become A Vishwaguru
• 135077 Tweets
Liverpool
• 131577 Tweets
Oscar
• 90737 Tweets
DAOU IN PATTAYA
• 81239 Tweets
Lando
• 66536 Tweets
Norris
• 63660 Tweets
McLaren
• 58318 Tweets
Colapinto
• 55818 Tweets
#MUNLIV
• 41318 Tweets
Piastri
• 41152 Tweets
Spurs
• 36431 Tweets
プロジェクトKV
• 32308 Tweets
台風11号
• 31590 Tweets
Newcastle
• 31445 Tweets
Sainz
• 29670 Tweets
ブルアカ
• 28209 Tweets
Tottenham
• 27272 Tweets
#f1jp
• 26972 Tweets
aiko
• 23939 Tweets
渡海先生
• 19402 Tweets
Nicolas Jackson
• 18411 Tweets
天城先生
• 15667 Tweets
Amad
• 14292 Tweets
wrwrd
• 13704 Tweets
Isak
• 11149 Tweets
In this video moderated by
@JohnPLeonardMD
, a panel of experts discuss the impact of
#COVID19
on hematology/oncology care delivery.
@drkomanduri
@DavidSteensma
@SagarLonialMD
@jaltmanmd
@mangarone23
Watch here:
0
12
22
Here,
@KristenCiombor
, MD, discussed the opportunities for checkpoint inhibition with MSI-H colorectal cancer, as presented at the 2023 World Congress on Gastrointestinal Cancers. Learn more:
#medtwitter
#onctwitter
#GIoncology
#WCGIC2023
0
4
16
Ghassan Abou-Alfa, MD, MBA,
@GABOUALFA
discusses the results from the ClarIDHy trial, which evaluated ivosidenib in IDH1-mutant advanced cholangiocarcinoma. Watch here:
1
4
15
Here,
@Dr_AmerZeidan
, MBBS, highlighted his treatment choices for a 74-year-old woman diagnosed with lower-risk myelodysplastic syndrome as part of the "How I Treat" series. Learn more here:
#onctwitter
#medtwitter
#hematology
#myelodysplasticsyndromes
0
3
15
At the 2023 Great Debates & Updates in Hematologic Malignancies
#GDUHem
meeting, Amer Zeidan, MBBS, MHS, discussed effective risk stratification among patients with
#MDS
.
@YaleCancer
@Dr_AmerZeidan
Learn more here:
@GreatDebatesCME
0
3
14
Here, Paolo Tarantino, MD, discusses discoveries made in the genomic characterizations and treatment of HER2-low, HER2-zero, and HER2-positive breast cancers, which he presented at the San Antonio Breast Cancer Symposium.
@DanaFarber
@PTarantinoMD
#SABCS
0
2
13
Dr. Shaji Kumar,
@myelomaMD
, from
@MayoClinic
, discusses MRD testing, its use in standard practice, and how this testing affects the treatment decision-making process for patients with
#myeloma
.
0
4
13
Mehdi Hamadani, MD,
@MediHumdani
,
@UWM
, discusses an
#analysis
evaluating the role of an autologous
#transplant
in relapsed DLBCL with the utilization of newer
#therapies
, specifically CAR T-cells.
Watch Here:
1
1
13
John Strickler, MD,
@DukeCancer
, discusses an analysis of the phase 2 MOUNTAINEER trial, in which tucatinib plus trastuzumab demonstrated clinically meaningful antitumor activity in metastatic
#colorectalcancer
.
@ESMOWorldGI
#WCGIC2022
Watch the video:
0
5
13
Here, Betty K. Hamilton, MD, discusses the findings of a pilot trial analyzing patient-reported outcomes for the management of patients with acute graft-versus-host-disease (
#GVHD
). Follow along here:
@hamiltkyb
@ClevelandClinic
0
1
12
At
#GDUGI2023
,
@SKamath_MD
spoke with us about his talk on ctDNA in the gastrointestinal cancer space!
#GastroOnc
#GICancer
@GreatDebatesCME
0
2
12
At the 2023 World Congress on Gastrointestinal Cancers James Harding, MD, presented data from the first-in-human phase 1 study of LY3410738. Learn more here:
#onctwitter
#medtwitter
#cholangiocarcinoma
0
6
11
Round 1 is now live! Listen as
@JTrentMDPhD
and
@DrRobinLJones
go head-to-head on whether the quality of evidence sufficiently supports the use of adjuvant/neoadjuvant chemotherapy for localized soft-tissue
#sarcoma
. Moderated by
@bvantine1
.
#Debate
3
6
11
In a recent podcast,
@gregoryjaune
, from
@UTHealthSA
, discusses his team’s findings from a multicenter study evaluating the long-term risk for anthracycline-related cardiomyopathy in survivors of childhood
#cancer
. Listen here:
0
5
10
Here, Joseph Mikhael, MD, MEd, shares his insights on treating patients with
#MultipleMyeloma
in early relapse, which he discussed at the 2023 Great Debates & Updates in Hematologic Malignancies conference
#GDUHem
.
@jmikhaelmd
@GreatDebatesCME
@cityofhope
0
1
10
At the 2024
@GreatDebatesCME
#GDUHem
meeting, Jessica Altman, MD,
@NorthwesternMed
, argues in favor of using sequential therapy over triplet therapy for patients with newly diagnosed
#AML
who are ineligible for intensive chemo. Learn more:
@jaltmanmd
0
4
10
Minouk Schoemaker, PhD, from
@ICR_London
, discusses the origin of the Premenopausal Breast Cancer Collaborative Group and the outcomes of their latest study examining the relationship between BMI and the risk for
#breastcancer
in premenopausal women.
0
4
8
At
#WorldGI2019
, Margaret Tempero, MD, presents, for the first time, results from the phase 3 RESOLVE trial, which assessed the safety & efficacy of ibrutinib plus nab-paclitaxel/gemcitabine in pancreatic cancer. Visit our newsroom for exclusive coverage:
1
2
10
At
#GDUHem
@JoshuaRichterMD
discussed promising novel advances in the multiple myeloma treatment landscape, including the use of t-cell redirection therapy and possible treatment approvals to come. Learn more:
#medtwitter
#onctwitter
0
2
10
Here, Philip Philip, MD, defended the position of doing next-generation sequencing for all patients with pancreatic ductal adenocarcinoma at the 2023 World Congress on Gastrointestinal Cancers. Learn more:
#medtwitter
#onctwitter
#WCGIC2023
#GIoncology
1
4
10
In this video,
@YJanjigianMD
,
@MSKCancerCenter
, discusses findings from a preliminary biomarker analysis of the ongoing DESTINY-Gastric03 trial.
@ESMOWorldGI
@myESMO
#WCGIC2022
Watch the video:
0
4
10
Christian Rolfo, MD, PhD, MBA, Dr(hc),
@ChristianRolfo
discusses his approach to treating
#patients
with ALK-positive
#NSCLC
, including those with newly diagnosed or crizotinib-refractory disease.
Learn More:
#medtwitter
#oncology
#patientcare
0
5
10
At the 2023 Great Debates & Updates in Hematologic Malignancies conference
#GDUHem
, Saad Usmani, MD, MBA, FACP, discussed novel and cellular therapies used to treat
#MultipleMyeloma
. Learn more:
@szusmani
@MSKCancerCenter
@GreatDebatesCME
0
3
9
Here, Monique Hartley-Brown, MD, MMSc, discusses initiatives to improve
#diversity
and
#accessibility
in trials for patients with multiple myeloma
#MM
, and advises on strategies to pursue these objectives at the 2023
#GDUHem
meeting.
@DanaFarber
@DrMHB1
0
1
9
Dr Abou-Alfa,
@GABOUALFA
,
@sloan_kettering
, discusses novel therapies and why
#etiology
is important in the treatment of hepatocellular
#carcinoma
in the second part of this interview during the virtual 2020
@ASCO
Annual Meeting.
Watch Here:
0
2
9
Follow along as Claire Harrison, MD, leads a discussion on
#PolycythemiaVera
and the importance of hematocrit control with Jean-Jacques Kiladjian, MD, and Alessandro Rambaldi, MD, in the first installment of a 4-part expert roundtable series.
@jjkiladjian
0
2
9
Here,
@OmidHamidMD
discussed results from a trial examining the combination treatment of fianlimab plus cemiplimab for patients with advanced melanoma, as presented at the 2023
@ASCO
annual meeting. Learn more:
#medtwitter
#onctwitter
#fianlimab
0
8
9
Here, Justin Kline, MD,
@UCCancerCenter
,
@UChicagoMed
, discussed a novel CD5 gene expression signature (CD5sig) that is a useful biomarker to identify
#DLBCL
subtypes vulnerable to
#BTK
inhibitor therapies. Learn more:
#MedTwitter
#Oncology
#OncologyNews
0
3
8
At the 2023
@ASCO
annual meeting, Emily C. Liang, MD, shared data on the long-term outcomes of patients treated in a phase 1 and 2 clinical trial of CD19-targeting CAR T-cell therapy for R/R chronic lymphocytic leukemia
#CLL
. Learn more here:
@emilyliangmd
0
1
8
Episode 4 of our 7 part web series is now available: COVID-19 & Hematologic Malignancies: Effective Management & Patient Experience from Seattle to Chicago. This is a free, accredited activity. Watch here:
1
3
9
First trial combining Immunotherapy and LAT for Oligometastatic NSCLC yields intriguing results. Joshua Bauml, MD,
@Jbauml
discusses the significance with OLN here:
0
5
9
In this interview with OLN, Dr Xiao Xu,
@YaleMed
talks about power morcellation at the time of hysterectomy/myomectomy and the associated mortality risk in occult uterine cancer. Read more here:
0
4
9
A wonderful discussion at
#WorldGI2019
between
@GABOUALFA
, Dr Arndt Vogel, and Dr Chris Verslype, about the REACH/REACH-2 clinical trial. Coming soon! View this video and more:
0
5
8
Othman Al-Sawaf, MD, University Hospital of Cologne, Germany,
@UKKoeln
,
discusses highlights from the phase 3 CLL14 trial, which looked at
#venetoclax
plus
#obinutuzumab
therapy for CLL.
Watch Here:
0
2
8
Here, Joshua Richter, MD, shares his presentation from the 2023 Great Debates & Updates in Hematologic Malignancies conference
#GDUHem
on therapies for older and more frail patients with
#MultipleMyeloma
.
@JoshuaRichterMD
@IcahnMountSinai
0
1
7
What's New in Anal Cancer over the Last 12 Months?
@CathyEngMD
, MD, FACP, FASCO, discussed the latest developments in anal cancer over the past 12 months with OLN at
@WCGIC
. You can watch now here:
0
1
8
Dr Holtan, (
@sghmd
),
@umnmedschool
, shares an overview of human chorionic gonadotropin and epidermal growth factor to treat aGVHD.
Watch here:
#medtwitter
#oncology
@UMNews
@ASH_hematology
0
0
8
Round 2, moderated by
@bvantine1
, is now live! Listen as
@JTrentMDPhD
and
@DrRobinLJones
#debate
whether the benefits of adjuvant/neoadjuvant chemotherapy in soft-tissue
#sarcoma
outweigh the associated toxicities. Who do you think won this round?
0
7
7
Jeffrey Rubnitz, MD, PhD,
@StJude
@StJudeResearch
discusses a study on the safety and activity of
#venetoclax
plus
#chemo
for young patients with heavily relapsed/refractory
#AML
.
Learn More:
#medtwitter
#pediatriccancer
#oncologynews
1
5
7
Here, Matthew Matasar, MD, shares updated results from a pivotal phase 2 study on the efficacy and safety of
#mosunetuzumab
monotherapy among patients with relapsed/refractory follicular lymphoma
#FL
. Learn more:
@DrMatasar
@RutgersCancer
#MedTwitter
0
3
7
Session moderator Gail Roboz, MD, is getting ready to kick off session III, which will focus on acute myeloid leukemia!
#LymphomaMyeloma2018
0
2
7
Now Available: Access meeting materials, including educational presentations, abstracts, posters, and livestreams from
#LymphomaMyeloma2018
@LMCongress
0
2
7
At the 2023 Great Debates and Updates in Gastrointestinal Malignancies
#GDUGI
meeting, Cathy Eng, MD, offered her perspectives on the current and upcoming clinical trials for treatments of anal cancer. Learn more:
@GreatDebatesCME
@CathyEngMD
1
3
7
Check out our interview with Jo Morris, PhD, BSc, on her team's study that found new functions of the BRCA1 gene in breast and ovarian cancers.
0
5
7
In this video, Matthew Matasar, MD, discusses upcoming studies and encouraging advances that show promise in the continually evolving treatment landscape for patients with follicular lymphoma
#FL
. Learn more:
@DrMatasar
@RutgersCancer
#MedTwitter
0
3
7
Join moderator
@bvantine1
as he kicks off a
#debate
between experts
@JTrentMDPhD
and Robin Jones, BSc, MB BS, MRCP, MD (Res), on the use of adjuvant and neoadjuvant chemotherapy in patients with soft-tissue
#sarcoma
.
#GreatDebatesinOncology
2
2
7
In
#BladderCancer
installment of
#HowITreat
,
@BenMironMD
presents the case of a patient with
#UrothelialCarcinoma
with spinal and liver metastasis. Follow along as Dr Miron share his considerations for this case!
0
0
7
Here, Ticiana Leal, MD, shares results from the phase 3
#LUNARtrial
, evaluating the use of tumor treating fields, as presented at the
#ASCO2023
annual meeting. Learn more here:
#onctwitter
#medtwitter
#NSCLC
0
3
6
#myeloma
is the second most common blood cancer in the world. Share your
#MYelomaSTORY
at an upcoming event. Use code MYELOMA to save $50 off your registration for
#GDUHEM
and
#LLMCongress2023
.
0
5
6
New: Free online CME activity: COVID-19 & Hematologic Malignancies. Episode 1 of this 6 part series will cover effective management from the east to west coast. Watch here:
0
4
6
Jeffrey Weber, MD, PhD, presents a guide for addressing immune-related adverse events in immuno-oncology at
#WorldGI2019
@WCGIC
0
3
6
ICYMI: Shwetal Mehta, PhD,
@IvyBrainTumCtr
talks about the clinical significance of a study evaluating the use of ribociclib in patients with recurrent glioblastoma. Check out the interview:
0
4
6
Emma Searle, MD discusses findings from the MajesTEC-2 trial, evaluating
#teclistamab
combined with subcutaneous
#daratumumab
and
#lenalidomide
in patients with
#MultipleMyeloma
. Learn more about
@DrEmmaSearle
's research here!
0
1
6
Andrea Sartore Bianchi, MD,
@andrea_sart
sat down with OLN to discuss the HER2 Pathway in gastrointestinal cancer at the 2019
@ESMO
World Congress on Gastrointestinal Cancer
@WCGIC
Watch the video here:
0
2
5
In this short podcast with OLN,
@DrDawnHershman
, MD, MS, discusses how the cost of breast cancer treatment is directly tied to therapy adherence. Listen here:
0
3
6
At the 2020 Great Debates and Updates in Hematologic Malignancies Meeting
@GreatDebatesHem
, Peter Voorhees, MD, debated Joseph Mikhael
@jmikhaelmd
, MD, Med, FRCPC, on the best approach to treating
#patients
with smoldering
#myeloma
.
Watch Here:
0
1
6
Sattva Neelapu, MD,
@MDAndersonNews
, discusses early results from the ALPHA study suggesting that ALLO-501 and ALLO-647 are safe and may be effective in LBCL and FL.
Watch Here:
0
2
6
"I take pride in the groundbreaking research we are able to highlight, for those who deserve answers, alongside the incredible people I am fortunate to collaborate with." -Alexis Hyams, Assistant Editor
@OLNEditorial
,
#InsideOLN
#WorldCancerDay
#worldcancerday2021
#MedTwitter
0
1
6
Here,
@TalhaBadarMD
,
@MayoClinic
, speaks on a real-world study on the efficacy of
#venetoclax
combined with
#HMA
therapy for patients with TP53-mutated
#AML
, which he presented at the
#ASH2023
meeting.
@ASH_hematology
#MedTwitter
#Oncology
#ASH
0
1
6
In the 3rd installment of a 4-part expert roundtable series, Claire Harrison, MD, leads a discussion on how to determine when first-line
#PolycythemiaVera
therapy is failing with Jean-Jacques Kiladjian, MD, and Alessandro Rambaldi, MD.
@jjkiladjian
0
1
6
At the 2024
@GreatDebatesCME
#GDU
in Hematologic Malignancies meeting,
@JoshuaRichterMD
,
@TischCancer
,
@IcahnMountSinai
, explores the role of MRD in multiple myeloma treatment, addressing whether it should be used to make clinical decisions. Learn more:
0
1
5
In this video, Dr Wang,
@michaelwangmd
,
@MDAndersonNews
, discusses the use of LOXO-305, a highly selective BTK inhibitor, in patients with pretreated MCL, WM, and other NHLs.
Watch Here:
0
2
5
In the first installment of this 3-part podcast series,
@DrJFriedberg
, from
@WilmotCancer
, discusses the current barriers to care for patients with aggressive lymphoma.
0
2
4
Experts detect gene that prevents immunotherapy from destroying cancer cells. OLN interviewed Robert K. Bradley, PhD,
@bradleybio
and Stephen J. Tapscott, MD, PhD
@fredhutch
about their findings, you can read the interview here:
0
0
5
Julie Gralow, MD,
@jrgralow
,
@SeattleCCA
,
@UW
, talks about how she and her co-investigators identified baseline risk factors associated with increases in AI nonadherence in
#patients
with
#breastcancer
.
Watch Here:
0
1
5
In the 2nd installment of a 4-part expert roundtable series, Claire Harrison, MD, leads a discussion on
#PolycythemiaVera
, aims of treatment, and choice of first-line therapy with Jean-Jacques Kiladjian, MD, and Alessandro Rambaldi, MD.
@jjkiladjian
0
3
5
According to Ignace Vergote, MD, and coauthors "a preliminary analysis of a prespecified exploratory subgroup of patients with TP53wt [endometrial cancer] showed promising results with selinexor maintenance therapy.” Learn more:
#medtwitter
#onctwitter
0
1
5
Ruben Mesa, MD, FACP,
@mpdrc
, Director, Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center, Texas,
@UTHealth
,
@UTHealthSAMDA
, explains current and emerging therapy options for
#patients
with
#myeloproliferative
neoplasms.
Watch Here:
0
4
5
Have you seen our interview with Ruben Mesa, MD, from
@MaysCancer
? Here,
@mpdrc
discusses the ongoing phase II study of luspatercept in subjects with myeloproliferative neoplasm-associated myelofibrosis and anemia.
0
3
5
Episode 6 of our 7 part web series is now available: COVID-19 & Hematologic Malignancies: Myeloid Malignancy Update with
@jmikhaelmd
and
@jaltmanmd
. This is a free, accredited activity. Watch here:
0
2
5
Follow along as
@EmilyBaumrinMD
, discusses her research on whether the severity of skin involvement of chronic graft-versus-host-disease is a prognostic marker for poorer outcomes in patients with chronic graft-versus-host-disease
#GVHD
.
@PennMedicine
0
1
5
In this short video, meeting chair,
@jmikhaelmd
, shares his insight on relapsed
#myeloma
, why he chose to practice in oncology, and why he's looking forward to the 2019 Great Debates and Updates in Hematologic Malignancies meeting series.
@GreatDebatesHem
0
3
5
Here, Abhay Singh, MD,
@ClevelandClinic
, shares his advice for treating patients with follicular lymphoma
#FL
to minimize the risk of adverse events and disease transformation to
#AML
/
#MDS
. Learn more:
@CloneTracker
#MedTwitter
#Oncology
#OncologyNews
0
2
5
The final episode of our 7-part series is now available: COVID-19 & Hematologic Malignancies: Infectious Disease Update with
@jmikhaelmd
and Dr. Michael Satlin. This is a free, accredited activity. Watch here:
1
1
5
Episode 5 of our 7 part web series is now available: COVID-19 & Hematologic Malignancies: Patient Experience Update with
@jmikhaelmd
and
@yelakbiru
. This is a free, accredited activity. Watch here:
0
3
5
Tanya Siddiqi, MD,
@cityofhope
, shares insights of a CD19-directed CAR T-cell therapy for patients with CLL.
Watch here:
#medtwitter
#oncology
0
1
5
In a panel moderated by
@EileenMOReilly
, Drs Golan, Hammel, and Macarulla discuss the POLO trial, which assessed the safety and efficacy of maintenance olaparib in metastatic pancreatic cancer. Visit to view this video and more from
#WorldGI2019
0
2
5
At
@ESMO
@WCGIC
, our expert roundtable consisting of
@GABOUALFA
, MD; Arndt Vogel, MD, PhD; and Chris Verslype, MD, PhD, FACP, discussed the clinical significance of the REACH and REACH-2 clinical trials.
#ESMO
#WorldGI
Watch the full discourse here:
0
1
4
Loretta Nastoupil, MD,
@MDAndersonNews
, discusses results from a study exploring obinutuzumab therapy plus lenalidomide in patients with untreated, high tumor burden FL.
#lymphoma
Watch here:
0
0
4
#GDUHem2019
is about to kick off day 1 with a session by
@jmikhaelmd
on novel small molecule inhibitors in
#MultipleMyeloma
0
3
4
Day 2 of
#GDUGI2022
Today's sessions include presentations and debates featuring
@ILSONDavid
,
@JavleMilind
,
@GABOUALFA
,
@aparna1024
, and more!
0
1
4
According to Muhammad Bilal Abid, MD, "Younger matched unrelated donors should be preferred over older matched sibling donors whenever both are available." Follow along as
@BilalAbidMD
shares more of his insights!
@MedicalCollege
0
1
4
Here,
@jasonlukemd
shares insight into the final distant metastasis-free survival analysis of
#KEYNOTE716
as presented at the
@ASCO
annual meeting. Learn more here:
#onctwitter
#medtwitter
#ASCO2023
#melanoma
#pembrolizumab
0
2
3
Ghassan Abou-Alfa, MD,
@GABOUALFA
,
@sloan_kettering
, discusses systemic and local therapy updates in hepatocellular carcinoma in the third part of this interview highlighting abstracts of note presented at the 2020
@ASCO
Annual Meeting.
Watch Here:
0
2
4
#March
is Myeloma Awareness Month, 15% of registration fees from the Lymphoma, Leukemia & Myeloma Congress this month will go to
@IMFmyeloma
|| Use the code MYELOMA when registering to
#takeaction
:
#myelomaaction
#medtwitter
#oncology
#heamtology
0
1
4
At the 2023
#GDUHem
meeting, Amer Zeidan, MBBS,
@YaleMed
, spoke on recent developments in risk stratification and treatment management among patients with high-risk and low-risk
#MDS
. Learn more:
@Dr_AmerZeidan
@GreatDebatesCME
#OncologyNews
#Oncology
0
1
4
At
#GDUHem
,
@jmikhaelmd
shared expert insight on when to choose CAR-T therapy versus bispecific antibodies in multiple myeloma treatment. Learn more:
#medtwitter
#onctwitter
0
1
3
In this panel discussion,
@DrAEvens
,
@DrJulieVose
,
@DrJFriedberg
and Dr. Stephen Ansell share key updates on the use of brentuximab vedotin for the treatment of classical Hodgkin
#lymphoma
. Check out the 6-part series here:
#lymsm
#ASH19
0
2
4
“This final analysis of ATEMPT confirms the outstanding efficacy of T-DM1 at preventing recurrences of stage I HER2-positive breast cancer,” concluded
@PTarantinoMD
, et al. Learn more:
#medtwitter
#onctwitter
0
2
4
Dr. Zeidan
@Dr_AmerZeidan
discusses results from a phase 2 study exploring azacitidine plus durvalumab in older patients with
#AML
and high-risk
#MDS
in this quick interview with OLN. Watch here:
0
1
4
In this 3-part podcast series, Gabriela Hobbs, MD, Clinical Director
@MassGeneralNews
, discusses the current therapies available for patients with chronic myeloid leukemia, and what the future outlook is for the treatment landscape of this disease.
0
1
3
Ghassan Abou-Alfa, MD,
@sloan_kettering
, discusses the ins and outs of
#telemedicine
use and importance of operational preparedness in the
#cancer
setting during the
#COVID19
pandemic.
Watch Here:
0
1
4
At
#GU24
, Saby George, MD, presented results from the CheckMate 67T trial. Learn more:
#medtwitter
#onctwitter
#ASCOGU24
0
0
3
Monique Hartley-Brown, MD, MMSc, discusses novel and emergent treatment developments for patients with R/R
#MultipleMyeloma
, which she presented at the 2023
#GDUHem
meeting. Learn more:
@DanaFarber
@GreatDebatesCME
@DrMHB1
#MedTwitter
0
2
3
According to results from the phase 3 GETUG-AFU-18 study, combined dose-escalated radiotherapy and long-term ADT improved bcPFS and survival outcomes among patients with high-risk prostate cancer. Learn more:
#medtwitter
#onctwitter
#GU24
#ASCOGU
0
1
3